Hormonal · MC4R · Sexual function

BioLibidoPT-141

Bremelanotide · MC4R agonist · sexual desire · FDA-approved (2019) · on-demand use

The ReferenceBenefits, protocols and preparationOpen the reference →
Purity
≥99%
Format
5mg · 10mg
Length
7 AA cyclic
Use
PRN
Molecule approved in United States · 2019What this means ›
🇺🇸 United States · Approved

The molecule is approved as a medicine in United States, under the brand Vyleesi. It was the first approved as-needed injectable of its kind, for hypoactive sexual desire disorder in premenopausal women (FDA, June 2019).

What is approved is the molecule under that pharmaceutical brand. Our vial is research material (RUO).

Source: FDA · Vyleesi (bremelanotide), 21-jun-2019

For research use only (RUO) Ships from Quito · EC 1-3 days · LATAM 4-10 Arrives damaged? We replace it free COA per batch
CAS · 189691-06-3 MW · 1025.16 Da Stock · Available
How it works

4 mechanisms. Central pathway, not vascular.

PT-141 acts on the central nervous system — not on peripheral circulation like Viagra/Cialis. That's why it works in both sexes and in cases where PDE5 inhibitors don't respond.

MC4R/MC3R agonist

Activates melanocortin receptors in the hypothalamus and stimulates the central dopaminergic pathway: desire starts in the brain, not in the circulation.

Evidence differs by sex

It acts on the MC4R receptor in both sexes, but the evidence is not symmetrical: the FDA approval (Vyleesi, 2019) covers hypoactive sexual desire disorder (HSDD) in premenopausal women. In men the studies are older and preliminary (phase 2 in erectile dysfunction) and that route was never approved.

Responds to mental state

Unlike sildenafil (purely vascular), PT-141 also acts on the mental and emotional component of desire. Useful when the cause is psychological or mixed.

Independent of testosterone

It does not change your own hormone levels. In the trials it worked the same with normal or low testosterone, and it is compatible with testosterone therapy.

Why combine it

Libido & desire

  1. 1You are here
    BioLibidoPT-141More sexual desire · Supports erection
  2. 2+ BioDriveKisspeptin+ Adds: Own testosterone without shutting the axis
See all combinations in the Consultation →
The compound

Technical description.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide, an analog of α-MSH (alpha-melanocyte-stimulating hormone). It acts as an agonist of the MC4R and MC3R melanocortin receptors in the central nervous system, mainly in the hypothalamus, where it stimulates the dopaminergic pathway of sexual desire and arousal.

SuperBio Labs PT-141 is supplied as a lyophilized powder with verified HPLC purity ≥99%. Every batch ships with an independent Certificate of Analysis confirming identity by LC-MS, peptide content (98–102%), and endotoxin levels (<1.0 EU/mg).

The pharmaceutical version of PT-141 (Vyleesi®) has been FDA-approved since 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, after two phase 3 trials with about 1,200 women. Unlike sildenafil or tadalafil, which act on blood vessels, PT-141 acts in the brain, on desire and arousal. In men there are phase 2 studies in erectile dysfunction, but that indication was never approved. It is used on demand, not daily.

Informed professional research use only.

Complete kit · ready to reconstitute.

Each order includes everything needed for your on-demand applications. No separate purchases required.

Vial + BWFI + syringes + alcohol swabs · kit contents
1× PT-141 5mg lyophilized vial
1× 3 ml BWFI vial (bacteriostatic water)
insulin syringes U-100 0.5ml 29G
alcohol wipes 70%
1× organizer box
1× printed reconstitution guide
1× PRN application protocol
1× batch COA (digital + printed)
Before you buy · from any store

How to choose where to buy peptides.

01
Per-batch, verifiable COA The certificate exists and can be checked — not "available on request".
→
02
HPLC purity + LC-MS identity How much is in the vial, and that it is the right peptide.
→
03
Endotoxins tested LAL test within range — not just purity.
→
04
2-8°C cold chain Documented end to end, not promised.
→
05
Traceability and support Lot number on the vial and someone who answers after.

This product meets all five — your batch COA ships with the kit.

Recommended application protocol.

The official protocol included in the kit: on-demand use, applied about 2 hours before, with no continuous cycle.

Reconstitution
1 ml (5 mg) · 2 ml (10 mg) of bacteriostatic water → 5 mg/ml
Your first time
Start below the standard dose and only go up if you tolerate it well
Standard dose
1.5 → 2 mg
Onset time
2–6 h after application
Duration of effect
8–24 hours
Maximum frequency
No more than 1×/24h · max 8 doses/month
Storage (reconstituted)
60 days refrigerated (2–8°C)
Important

ALWAYS start with a 0.5 mg dose to assess individual response and tolerance (especially nausea, the most common side effect). Do NOT combine with poppers, simultaneous sildenafil/tadalafil, or antihypertensive medication without medical consultation.

When to use PT-141.

Low sexual desire in women

Hypoactive sexual desire before menopause · the FDA-approved indication.

When sildenafil is not enough

Men for whom sildenafil or tadalafil don't work · phase 2 evidence, never approved.

Mental or emotional cause

When stress or anxiety weigh more than circulation · it works through the central pathway.

On antidepressants

Low desire linked to antidepressants · works through another pathway without changing the medication · limited evidence.

Only when you need it

Occasional use · at most 1 dose in 24 hours and 8 per month · no continuous protocol needed.

Honest side effects.

The most common side effect is nausea. In the phase 3 trials 40% of women had it (21% with the first dose); 13% needed an anti-nausea medicine and 8% stopped because of it. It usually appears within the first hour and passes in 1–2 hours. That is why it makes sense to start with a lower test dose.

Others: facial flushing · occasional headache · a temporary rise in blood pressure (about 6/3 mmHg, peaking at 2–4 hours, back to normal in about 12 hours) · darkening of freckles or moles with very frequent use (rare). Not used with uncontrolled hypertension or cardiovascular disease. It lowers the absorption of oral naltrexone. A light meal beforehand reduces nausea.

Technical specifications

Also known asBremelanotide
CAS number189691-06-3
Molecular weight1025.16 Da
SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Purity (HPLC)≥99%
FormatLyophilized powder
Quantity5 / 10 mg per vial
Endotoxins<1.0 EU/mg
Storage−20 °C, protected from light
Clinical referenceVyleesi® (Palatin Technologies, FDA 2019)
UseUse under professional judgment

Also in Hormonal / Vitality